Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery
This article was originally published in PharmAsia News
Executive Summary
Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development
You may also be interested in...
Nobel Laureate Richard Roberts On Bringing New England BioLabs To Asia: An Interview With PharmAsia News
Nobel Prize winner Richard Roberts was recently in Asia for Singapore’s Global Young Scientist Summit, and he shared his thoughts about launching a business model that funnels profits into basic research globally and why companies should not be profit focused.
Roche's Joe McCracken On Early-stage Partnering In Asia: An Interview With PharmAsia News (Part 1 Of 2)
CHICAGO - Joe McCracken was a longtime head of business development for Genentech before he was brought into the Roche Group as Asia Regional Head for Roche Pharma Partnering, so he knows a few things about incorporating two organizations' visions of research projects when it comes to partnering.
Roche's Joe McCracken On Early-stage Partnering In Asia: An Interview With PharmAsia News (Part 1 Of 2)
CHICAGO - Joe McCracken was a longtime head of business development for Genentech before he was brought into the Roche Group as Asia Regional Head for Roche Pharma Partnering, so he knows a few things about incorporating two organizations' visions of research projects when it comes to partnering.